Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines
Loading...
Files
Accepted Version
Supporting Information
Date
2020-07-21
Authors
Agache, Ioana
Song, Yang
Posso, Margarita
Alonso-Coello, Pablo
Rocha, Claudio
Solà, Ivan
Beltran, Jessica
Akdis, Cezmi A.
Akdis, Mubeccel
Brockow, Knut
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Inc.
Published Version
Abstract
This systematic review evaluates the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled moderate-to-severe atopic dermatitis (AD). Pubmed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important AD-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Seven RCTs including 1845 subjects >12 years treated with dupilumab 16 to 52 weeks were evaluated. For adults, there is high certainty that dupilumab decreases SCORAD (MD -30,72; 95% CI -34,65% to -26,79%) and EASI-75 (RR 3.09; 95% CI 2.45 to 3.89), pruritus (RR 2.96; 95% CI 2.37 to 3.70), rescue medication (RR 3.46; 95% CI 2.79 to 4.30), sleep disturbance (MD -7.29; 95% CI -8.23 to -6.35) and anxiety/depression (MD -3.08; 95% CI -4.41 to -1.75) and improves quality of life (MD -4.80; 95% CI -5.55 to -4.06). The efficacy for adolescents is similar. Dupilumab-related adverse events (AEs) slightly increase (low certainty). The evidence for dupilumab-related serious AE is uncertain. The incremental cost-effectiveness ratio ranged from 28 500 pound (low certainty) to 124 541 US$ (moderate certainty). More data on long-term safety are needed both for children and for adults, together with more efficacy data in the paediatric population.Registration: PROSPERO (CRD42020153645).
Description
Keywords
Economic evaluations , Allergic diseases , Quality , Validation , Consensus , Cost , Information , Reliability , Euronheed , Pruritus , Atopic dermatitis , EASI , SCORAD , Dupilumab , Cost-effectiveness
Citation
Agache, I., Song, Y., Posso, M., Alonso‐Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C.A., Akdis, M., Brockow, K. and Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C., Palomares, O. and Jutel, M. (2020) 'Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines', Allergy, 76(1), pp. 45-58. doi: 10.1111/all.14510
Link to publisher’s version
Copyright
© 2020, EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. This is the peer reviewed version of the following item Agache, I., Song, Y., Posso, M., Alonso‐Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C.A., Akdis, M., Brockow, K. and Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C., Palomares, O. and Jutel, M. (2020) 'Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines', Allergy, 76(1), pp. 45-58, doi: 10.1111/all.14510, which has been published in final form at: https://doi.org/10.1111/all.14510. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.